These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29696172)

  • 1. Sharing some interim data in trial monitoring can mislead or unmask trial investigators: A scenario-based survey of trial experts.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Contemp Clin Trials Commun; 2017 Sep; 7():81-85. PubMed ID: 29696172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of professional views on sharing interim results by the Data Safety Monitoring Board (DSMB): what to share, with whom and why.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 May; 19(1):281. PubMed ID: 29784030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring factors associated with views on sharing of certain interim trial result measures by the data safety monitoring board (DSMB) with non-DSMB members.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 Nov; 19(1):621. PubMed ID: 30419939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.
    Borg Debono V; Mbuagbaw L; Thabane L
    Trials; 2017 Mar; 18(1):120. PubMed ID: 28279205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.
    Gewandter JS; Kitt RA; Hunsinger MR; Poku J; Lozano J; Chaudari J; Evans S; Gross RA; McDermott MP; Rowbotham MC; Turk DC; Dworkin RH
    J Clin Epidemiol; 2017 Mar; 83():101-107. PubMed ID: 28126598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data and safety monitoring during randomized controlled trials of nursing interventions.
    Artinian NT; Froelicher ES; Vander Wal JS
    Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should data and safety monitoring boards share confidential interim data?
    Dixon DO; Lagakos SW
    Control Clin Trials; 2000 Feb; 21(1):1-6; discussion 54-5. PubMed ID: 10659999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Securely sharing DSMB reports to speed decision making from multiple, concurrent, independent studies of similar treatments in COVID-19.
    Dilts NA; Harrell FE; Lindsell CJ; Nwosu S; Stewart TG; Shotwell MS; Pulley JM; Edwards TL; Serdoz ES; Benhoff K; Bernard GR
    J Clin Transl Sci; 2022; 6(1):e49. PubMed ID: 35656334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When inferiority meets non-inferiority: implications for interim analyses.
    Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
    Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience collecting interim data on mortality: an example from the RALES study.
    Wittes J; Palensky J; Asner D; Julian D; Boissel JP; Furberg CD; Kulbertus H; Pocock S; Roniker B
    Curr Control Trials Cardiovasc Med; 2001; 2(1):59-62. PubMed ID: 11806773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DSMB. 1. What role, what responsibilities?].
    Brun-Buisson C
    Med Sci (Paris); 2005 Jan; 21(1):78-82. PubMed ID: 15639025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DSMB case study: decision making when a similar clinical trial is stopped early.
    Hillman DW; Louis TA
    Control Clin Trials; 2003 Feb; 24(1):85-91. PubMed ID: 12559646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidance on interim analysis methods in clinical trials.
    Ciolino JD; Kaizer AM; Bonner LB
    J Clin Transl Sci; 2023; 7(1):e124. PubMed ID: 37313374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
    Cairns JA; Wittes J; Wyse DG; Pogue J; Gent M; Hirsh J; Marler J; Pritchett EL
    Am Heart J; 2008 Jan; 155(1):33-41. PubMed ID: 18082486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim monitoring in a treatment strategy trial with a composite primary endpoint.
    Kang M; Grund B; Hunsberger S; Glidden D; Volberding P
    Contemp Clin Trials; 2019 Nov; 86():105846. PubMed ID: 31520741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.